A Phase 2 interventional study of MORAb-202 and Paclitaxel in Neoplasms, Ovarian, sponsored by Bristol-Myers Squibb. Terminated at 50 sites in 9 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Business objectives have changed.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies testing paclitaxel in Ovarian Neoplasms — 13 open to participants now, 21 under way, 6 of them phase 3. Paclitaxel · Ovarian Neoplasms.
Among the 155 studies testing paclitaxel in Ovarian Neoplasms, this one is the 39th largest by enrollment of the 143 interventional ones that give a count, is one of 5 that started in 2023, is one of 83 in phase 2, and was the 147th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 155 studies testing paclitaxel in Ovarian Neoplasms are open now, in 9 countries. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18+ · Women only
ARCAGY/ GINECO GROUP · Sites in France, Italy, Japan and 1 more country
Ages 18+ · Women only
The University of Hong Kong · Sites in Hong Kong
Ages 18+ · Women only
Anhui Provincial Cancer Hospital · Sites in China
Ages 18–75 · Women only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 93 · Phase 3 28 · Phase 4 1
First in 1991; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 50 across the 143 interventional studies. Of the 107 that completed or were terminated, 41 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 155 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 8 studies filed under Ovarian Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing paclitaxel in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06476184Phase 3ARCAGY/ GINECO GROUPUtility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery | 2027-06 |
| NCT06492070Emory UniversityCryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers | 2026-12-31 |
| NCT05636111M.D. Anderson Cancer CenterPhase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | 2026-12-31 |
| NCT01970722City of Hope Medical CenterSurgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer | 2027-01-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 155 studies testing paclitaxel in Ovarian Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical Conditions
Physical and Laboratory Test Findings
Allergies and Adverse Drug Reactions
Other protocol-defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: MORAb-202
Drug: Paclitaxel · Drug: Pegylated Liposomal Doxorubicin (PLD) · Drug: Topotecan
Specified dose on specified days
Also known as: BMS-986445, Farletuzumab Ecteribulin
Specified dose on specified days
Also known as: Bendalis
Specified dose on specified days
Also known as: Caelyx
Specified dose on specified days
Also known as: Hycamtin
Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment
Objective Response Rate (ORR) is defined as the number of randomized participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on investigator assessments \[using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\], divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: From the date of randomization to the date of first objectively-documented progression or the date of subsequent therapy (Up to approximately 70 weeks)
Number of Participants With Treatment-Related Adverse Event (TRAEs) Leading to Discontinuation Within 6 Months From First Dose
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.
Time frame: From first dose of study medication up to 6 months
Number of Participants With Adverse Events (AEs)
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.
Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Number of Participants With Serious Adverse Events (SAEs)
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Number of Participants With AEs Leading to Discontinuation
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.
Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Number of Participants With Treatment-Related AEs
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.
Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Number of Participants With Treatment-Related SAEs
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Number of Participants With AEs of Special Interest (AESIs)
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention. An adverse event of special interest (AESI) is an AE (serious or nonserious) of scientific and medical concern specific to the sponsor's product/program that may require further investigation. AESIs for MORAb-202 include infusion-related reactions and interstitial lung disease (ILD)/pneumonitis. The number of participants experiencing at least one AESI was assessed during the study.
Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Number of Participants Who Died
Number of participants who died during the study.
Time frame: From first dose of study medication until death due to any cause (up to 136 weeks)
Number of Participants With Grade 3-4 Laboratory Abnormalities
Number of participants experiencing most frequently reported clinical abnormalities in laboratory testing including hematology, chemistry, liver function, and renal function. Laboratory findings are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
Time frame: From first dose of study treatment through 30 days after the last dose of study treatment (up to approximately 25 months)
Disease Control Rate (DCR) by RECIST v1.1 Per Investigator Assessment
Disease Control Rate (DCR) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on investigator assessments (using RECIST v1.1) divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression). Based on Clopper and Pearson estimates of duration of response
Time frame: From randomization until disease progression, withdrawal from study treatment, initiation of new therapy, or study completion, whichever occurred first (up to approximately 136 weeks)
Duration of Response (DoR) by RECIST v1.1 Per Investigator Assessment
Duration of Response (DoR) is defined as the time between the date of first documented response (CR or PR) confirmed, to the date of the first objectively documented tumor progression by investigator (per RECIST v1.1) or death, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression). Based on Kaplan-Meier estimates of duration of response
Time frame: From first documented response (complete response or partial response) until first documented disease progression or death, whichever occurred first (up to approximately 136 weeks)
Progression-free Survival (PFS) by RECIST v1.1 Per Investigator Assessment
Progression-free Survival (PFS) is defined as the time between the date of randomization and the first date of documented progression, per investigator assessments (using RECIST v1.1), or death due to any cause, whichever occurs first. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression). Based on Kaplan-Meier estimates of progression-free survival
Time frame: From the date of randomization to the first date of documented progression, or death whichever occurs first (Up to approximately 136 weeks)
| Milestone | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Started | 70 | 36 |
| Completed | 70 | 34 |
| Not completed | 0 | 2 |
| Milestone | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Started | 70 | 34 |
| Completed | 2 | 0 |
| Not completed | 68 | 34 |
| Withdrew: Study terminated by sponsor | 0 | 1 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Other reasons | 1 | 2 |
| Withdrew: Progressive disease | 64 | 25 |
| Withdrew: Withdrawal by subject | 0 | 4 |
Objective Response Rate (ORR) is defined as the number of randomized participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on investigator assessments \[using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\], divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Percent of participants | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment | 20.0 (11.4 to 31.3) | 13.9 (4.7 to 29.5) |
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.
| Participants | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Number of Participants With Treatment-Related Adverse Event (TRAEs) Leading to Discontinuation Within 6 Months From First Dose | 2 | 0 |
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.
| Participants | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 67 | 32 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 19 | 11 |
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.
| Participants | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Number of Participants With AEs Leading to Discontinuation | 4 | 1 |
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention.
| Participants | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Number of Participants With Treatment-Related AEs | 53 | 29 |
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.
| Participants | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Number of Participants With Treatment-Related SAEs | 1 | 2 |
An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after starting study treatment, whether or not considered related to the study intervention. An adverse event of special interest (AESI) is an AE (serious or nonserious) of scientific and medical concern specific to the sponsor's product/program that may require further investigation. AESIs for MORAb-202 include infusion-related reactions and interstitial lung disease (ILD)/pneumonitis. The number of participants experiencing at least one AESI was assessed during the study.
| Participants | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Infusion-related reactions | 1 | 1 |
| Interstitial lung disease (ILD) | 3 | 0 |
| Pneumonitis | 13 | 0 |
Number of participants who died during the study.
| Participants | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Number of Participants Who Died | 36 | 20 |
Number of participants experiencing most frequently reported clinical abnormalities in laboratory testing including hematology, chemistry, liver function, and renal function. Laboratory findings are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.
| Participants | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Grade 3: Absolute Lymphocytes Decreased | 4 | 0 |
| Grade 3: Absolute Neutrophil Decreased | 3 | 9 |
Disease Control Rate (DCR) is defined as the number of randomized participants who achieve a BOR of confirmed CR, confirmed PR, or stable disease (SD), based on investigator assessments (using RECIST v1.1) divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression). Based on Clopper and Pearson estimates of duration of response
| Percent of participants | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Disease Control Rate (DCR) by RECIST v1.1 Per Investigator Assessment | 80.0 (68.7 to 88.6) | 69.4 (51.9 to 83.7) |
Duration of Response (DoR) is defined as the time between the date of first documented response (CR or PR) confirmed, to the date of the first objectively documented tumor progression by investigator (per RECIST v1.1) or death, whichever occurs first. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression). Based on Kaplan-Meier estimates of duration of response
| Months | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Duration of Response (DoR) by RECIST v1.1 Per Investigator Assessment | 4.44 (2.79 to 7.13) | 7.62 (2.37 to NA) |
Progression-free Survival (PFS) is defined as the time between the date of randomization and the first date of documented progression, per investigator assessments (using RECIST v1.1), or death due to any cause, whichever occurs first. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of at least 5mm (Note: The appearance of 1or more new lesions is also considered progression). Based on Kaplan-Meier estimates of progression-free survival
| Months | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) by RECIST v1.1 Per Investigator Assessment | 4.01 (2.79 to 4.67) | 4.30 (3.71 to 5.55) |
Objective Response Rate (ORR) is defined as the number of randomized participants who achieve a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), based on investigator assessments \[using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\], divided by the number of all randomized participants. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Percent of participants | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment | 21.4 (12.5 to 32.9) | 16.7 (6.4 to 32.8) |
Collected over Participants were assessed for all-cause mortality from randomization until death or study completion (up to approximately 136 weeks). Serious Adverse Events (SAEs) and Other Adverse Events (AEs) from first dose of study medication through 100 days after the last dose of study treatment (up to approximately 119 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MORAb-202 | 36/70 (51.4%) | 22/70 (31.4%) | 61/70 (87.1%) |
| Investigator's Choice (IC) Chemotherapy | 20/36 (55.6%) | 11/34 (32.4%) | 31/34 (91.2%) |
| Event | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| Intestinal obstructionGastrointestinal disorders | 5/70 | 3/34 |
| Intestinal pseudo-obstructionGastrointestinal disorders | 1/70 | 2/34 |
| PyrexiaGeneral disorders | 1/70 | 2/34 |
| Abdominal painGastrointestinal disorders | 3/70 | 0/34 |
| Small intestinal obstructionGastrointestinal disorders | 3/70 | 0/34 |
| AscitesGastrointestinal disorders | 0/70 | 1/34 |
| Duodenal obstructionGastrointestinal disorders | 1/70 | 1/34 |
| IleusGastrointestinal disorders | 2/70 | 1/34 |
| Rectal haemorrhageGastrointestinal disorders | 0/70 | 1/34 |
| Head injuryInjury, poisoning and procedural complications | 0/70 | 1/34 |
| Event | MORAb-202 | Investigator's Choice (IC) Chemotherapy |
|---|---|---|
| NauseaGastrointestinal disorders | 17/70 | 15/34 |
| NeutropeniaBlood and lymphatic system disorders | 7/70 | 11/34 |
| ConstipationGastrointestinal disorders | 17/70 | 9/34 |
| Neutrophil count decreasedInvestigations | 2/70 | 9/34 |
| AnaemiaBlood and lymphatic system disorders | 10/70 | 8/34 |
| Abdominal painGastrointestinal disorders | 15/70 | 3/34 |
| StomatitisGastrointestinal disorders | 0/70 | 7/34 |
| FatigueGeneral disorders | 11/70 | 7/34 |
| HeadacheNervous system disorders | 14/70 | 1/34 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 13/70 | 0/34 |
| Age, Continuous(Years) | MORAb-202 | Investigator's Choice (IC) Chemotherapy | Total |
|---|---|---|---|
| Mean | 58.3 ± 9.15 | 61.3 ± 12.16 | 59.3 ± 10.31 |
| Sex: Female, Male(Participants) | MORAb-202 | Investigator's Choice (IC) Chemotherapy | Total |
|---|---|---|---|
| Female | 70 | 36 | 106 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | MORAb-202 | Investigator's Choice (IC) Chemotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 7 | 19 |
| Not Hispanic or Latino | 57 | 29 | 86 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | MORAb-202 | Investigator's Choice (IC) Chemotherapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 17 | 11 | 28 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 50 | 24 | 74 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosure-commitment.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · www.bms.com
Ran from Feb 2023 to primary completion in Jun 2024, 16 months.
Results were first posted in Jul 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
Business objectives have changed.
Business objectives have changed.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: MORAb-202 · Paclitaxel · Liposomal doxorubicin · Topotecan